146 related articles for article (PubMed ID: 35805038)
1. Predominance of
Pujol P; Yauy K; Coffy A; Duforet-Frebourg N; Gabteni S; Daurès JP; Penault Llorca F; Thomas F; Hughes K; Turnbull C; Galibert V; Rideau C; Corsini C; Collet L; You B; Geneviève D; Philippe N
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805038
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Hur JY; Kim JY; Ahn JS; Im YH; Lee J; Kwon M; Park YH
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455662
[TBL] [Abstract][Full Text] [Related]
4. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
5. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
Turan V; Lambertini M; Lee DY; Wang E; Clatot F; Karlan BY; Demeestere I; Bang H; Oktay K
J Clin Oncol; 2021 Jun; 39(18):2016-2024. PubMed ID: 33891474
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
9. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
Yoshihara K; Enomoto T; Aoki D; Watanabe Y; Kigawa J; Takeshima N; Inomata H; Hattori K; Jinushi M; Tsuda H; Sugiyama T
Cancer Sci; 2020 Sep; 111(9):3350-3358. PubMed ID: 32495382
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
11. Germline
de Jonge MM; Ritterhouse LL; de Kroon CD; Vreeswijk MPG; Segal JP; Puranik R; Hollema H; Rookus MA; van Asperen CJ; van Leeuwen FE; Smit VTHBM; Howitt BE; Bosse T;
Clin Cancer Res; 2019 Dec; 25(24):7517-7526. PubMed ID: 31492746
[TBL] [Abstract][Full Text] [Related]
12. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the international prevalence of
Armstrong N; Ryder S; Forbes C; Ross J; Quek RG
Clin Epidemiol; 2019; 11():543-561. PubMed ID: 31372057
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Cancers in
Smith ES; Da Cruz Paula A; Cadoo KA; Abu-Rustum NR; Pei X; Brown DN; Ferrando L; Sebastiao APM; Riaz N; Robson ME; Soslow RA; Reis-Filho JS; Mandelker D; Weigelt B
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914019
[TBL] [Abstract][Full Text] [Related]
16. Germline and Somatic mutations in postmenopausal breast cancer patients.
Nagy TR; Maistro S; Encinas G; Katayama MLH; Pereira GFL; Gaburo-Júnior N; Franco LAM; Gouvêa ACRC; Diz MDPE; Leite LAS; Folgueira MAAK
Clinics (Sao Paulo); 2021; 76():e2837. PubMed ID: 34287479
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in
Vocka M; Zimovjanova M; Bielcikova Z; Tesarova P; Petruzelka L; Mateju M; Krizova L; Kotlas J; Soukupova J; Janatova M; Zemankova P; Kleiblova P; Novotny J; Konopasek B; Chodacka M; Brychta M; Sochor M; Smejkalova-Musilova D; Cmejlova V; Kozevnikovova R; Miskarova L; Argalacsova S; Stolarova L; Lhotova K; Borecka M; Kleibl Z
Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141992
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
[TBL] [Abstract][Full Text] [Related]
19. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
20. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
